Interesting paper on new solutions for making transfusions safer. The only aspect which is missing is a better education of the staff involved in hemotherapy, which is even more important than monitoring, etc. – Volker Kretschmer
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly replaced now with the once weekly dose, starting at 40,000 U SQ. – David H. Henry
This is an introduction for a supplement to the Canadian Journal of Anesthesia reporting proceedings of a satellite symposium presented at the 2002 Canadian Anesthesiologists’ Society Annual Meeting. It highlights the role of rFVIIa in managing bleeding in hemophilia patients with inhibitors, and the increasing number of case reports and studies in its role in […]
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales.
This helpful article offers increased understanding and ability to utilize the functional assessment of cancer therapy (FACT) scale. – Patricia Ford
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early response to epoetin… in this case at 4 weeks. Sadly, we still know that about two thirds of patients respond, but we cannot predict at […]
This is an interesting review on the use of continuous infusion of coagulation factor products over the last 11 years. It concludes that effects were favorable in comparison to intermittent bolus infusions. It suggests that continuous infusion has the advantage of maintaining a therapeutic level of the factor, and is associated with decrease in factor […]
This is a case report of successfully treating hemorrhage with rFVIIa in four patients with factor VIII and one with factor V inhibitor. One patient was initially treated with APCC (Autoplex) and blood products unsuccessfully. The authors confirm the efficacy and safety of rFVIIa and suggest carrying out cost effectiveness analysis. Further information is required […]
Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
This is a very important study as it has long been debated whether relevant amounts of free iron circulate after the administration of parenteral iron. The study confirms that this is the case. However, it is not known whether this is of clinical relevance (depending also on the total amount and time of usage of […]
The authors evaluated a low dose iron substitution scheme for the effectiveness in patients with peritoneal dialysis: 50 mg iron sucrose every other week is effective in patients with ferritin levels < 100 g/L (regarded as iron deficiency); 50 mg iron sucrose once a month did not affect EPO dosing in patients with ferritin levels […]
Epinephrine versus epinephrine plus fibrin glue injection in peptic ulcer bleeding: a prospective randomized trial.
A useful study (notwithstanding power) and review of current practices. – F. Regan and M. Contreras.
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
This article reports 2 patients with severe thrombocytopenia and severe hemorrhage which did not respond to standard therapy and platelet transfusion, but responded quickly to administration of a single dose of rFVIIa. The first patient had Waldenstoms macroglobulinemia and immune thrombocytopenia, and the second one had acute lymphoblastic leukemia. No adverse effects for rFVIIa were […]
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
This study reports the effective use of rFVIIa in covering 20 surgical procedures in 12 patients with hemophilia VIII with high inhibitors, in addition to treating 6 episodes of severe bleeding in 3 patients successfully. All but one of the surgical procedures were insertion or removal of a central venous access device. This paper again […]
Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
The authors from Taiwan state that they used “Ferrum Hausmann, a ferric polymaltose complex.” Under the same name (Ferrum Hausmann), iron saccharate (identical to iron sucrose) has been licensed in several European countries. The confusion concerning various iron sugar compounds gets even greater when one considers that “ferric polymaltose complex” was reported as being used […]
This study raises two important questions: First, are the observed adverse events upon high dose iron dextran users due to confounding variables such as comorbidity, or are they true iron dextran effects? Second, if they are true iron dextran effects, are they caused by the iron or the dextran? – C. Gasche.
This article raises awareness of the occurrence of acquired FVIII inhibitor postoperatively. One patient developed an inhibitor to FVIII 4 days after surgery for correction of abdominal hernia and bleeding was treated successfully with rFVIIa and immunosuppression. The second patient had severe bleeding 14 days post cholecystectomy due to an acquired FVIII inhibitor, but diagnosis […]